Williamson - Revision history

M.bennett at 02:56, 24 August 2022

2022-08-24T02:56:33Z

M.bennett at 23:34, 27 September 2021

2021-09-27T23:34:55Z

M.bennett at 04:25, 27 August 2020

2020-08-27T04:25:23Z

Gordoben: Imported from Wikispaces

2017-11-26T22:40:32Z

Imported from Wikispaces

New page

==No data on the use of hyperbaric oxygen for open tibial fractures==
==Clinical bottom line:==
{|
| '''1. Trial abandoned having recruited only 17 patients in total (target 36 in each group)'''
|-
|}
**Citation/s:''' Williamson OD, Millar I, Venturoni C. Hyperbaric oxygen and the management of open tibial fractures. Journal of Bone and Joint Surgery – British Volume, Orthopaedic proceedings 2005; 88-B(Suppl II):323.

**Lead author's name and fax:''' O.D.Williamson, I. Millar
**Three-part Clinical Question:''' Does HBOT improve soft tissue healing in adult patients with open tibial fractures?

**Search Terms:''' Open tibial fracture hyperbaric oxygen therapy
**The Study:'''

Non-blinded randomised controlled trial.

**The Study Patients:''' Adults with lower leg fractures requiring extensive soft tssue and/or vascular repair (Gustillo class 3B and 3C fractures).

**Control group''': No HBOT, usual management.

**Experimental group''': As above plus HBOT – dose not reported
**The Evidence:'''
None reported.
**Comments:'''

1. Reasons for cancellation given were slower than expected recruitment rate and difficulty engaging orthopaedic team owing to pre-existing belief that HBO was efficacious.
2.No report of any outcome from the 17 enrolled patients.
**Appraised by:''' Craig Wilson c.c.wilson@live.co.uk; Friday, 24 November 2017

Email: c.c.wilson@live.co.uk

**Kill or Update By:''' November 2020

[[File:sumhorsa.gif|center|sumhorsa.gif]]

==[[Acute ischaemia | BACK]]==

@@ Line 1: / Line 1: @@
-<span style="line-height:normal">'''<span style="font-size:18.0pt"><span style="font-family:" times="" new="" roman",serif"="">No data on the use of hyperbaric oxygen for open tibial fractures</span></span>'''</span>
+<span style="line-height:normal">'''<span style="font-size:18.0pt"><span style="font-family:">No data on the use of hyperbaric oxygen for open tibial fractures</span></span>'''</span>
-<span style="line-height:normal">'''<span style="font-size:14.0pt"><span style="font-family:" times="" new="" roman",serif"="">Clinical bottom line:</span></span>'''</span>
+<span style="line-height:normal">'''<span style="font-size:14.0pt"><span style="font-family:">Clinical bottom line:</span></span>'''</span>
 {| class="Table" style="border:undefined"
 |-
+|
-<span style="line-height:normal"><span style="font-size:14.0pt"><span style="font-family:" times="" new="" roman",serif"="">1. Trial abandoned having recruited only 17 patients in total (target 36 in each group)</span></span></span>
+<span style="line-height:normal"><span style="font-size:14.0pt"><span style="font-family:">1. Trial abandoned having recruited only 17 patients in total (target 36 in each group)</span></span></span>
 |}
@@ Line 13: / Line 13: @@
 ----
-<span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">Citation/s:</span></span>'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">1. Williamson OD, Millar I, Venturoni C. Hyperbaric oxygen and the management of open tibial fractures. Journal of Bone and Joint Surgery – British Volume, Orthopaedic proceedings 2005; 88-B(Suppl II):323.</span></span></span>
+<span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:">Citation/s:</span></span>'''<span style="font-size:12.0pt"><span style="font-family:">1. Williamson OD, Millar I, Venturoni C. Hyperbaric oxygen and the management of open tibial fractures. Journal of Bone and Joint Surgery – British Volume, Orthopaedic proceedings 2005; 88-B(Suppl II):323.</span></span></span>
-<span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">Lead author's name and fax:</span></span>'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">I. Millar I.Millar@alfred.org.au</span></span></span>
+<span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:">Lead author's name and fax:</span></span>'''<span style="font-size:12.0pt"><span style="font-family:">I. Millar I.Millar@alfred.org.au</span></span></span>
-<span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">Three-part Clinical Question:</span></span>'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">Does HBOT improve soft tissue healing in adult patients with open tibial fractures?</span></span></span>
+<span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:">Three-part Clinical Question:</span></span>'''<span style="font-size:12.0pt"><span style="font-family:">Does HBOT improve soft tissue healing in adult patients with open tibial fractures?</span></span></span>
-<span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">Search Terms:</span></span>'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">Open tibial fracture; crush injury</span></span></span>
+<span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:">Search Terms:</span></span>'''<span style="font-size:12.0pt"><span style="font-family:">Open tibial fracture; crush injury</span></span></span>
-<span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">The Study:</span></span>'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">Non-blinded randomised controlled trial.</span></span></span>
+<span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:">The Study:</span></span>'''<span style="font-size:12.0pt"><span style="font-family:">Non-blinded randomised controlled trial.</span></span></span>
-<span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">The Study Patients:</span></span>'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">Adults with lower leg fractures requiring extensive soft tssue and/or vascular repair (Gustillo class 3B and 3C fractures).</span></span></span>
+<span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:">The Study Patients:</span></span>'''<span style="font-size:12.0pt"><span style="font-family:">Adults with lower leg fractures requiring extensive soft tssue and/or vascular repair (Gustillo class 3B and 3C fractures).</span></span></span>
-<span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">Control group:''</span></span>'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">No HBOT, usual management.</span></span></span>
+<span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:">Control group:</span></span>'''<span style="font-size:12.0pt"><span style="font-family:">No HBOT, usual management.</span></span></span>
-<span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">Experimental group:</span></span>'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">As above plus HBOT – dose not reported.</span></span></span>
+<span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:">Experimental group:</span></span>'''<span style="font-size:12.0pt"><span style="font-family:">As above plus HBOT – dose not reported.</span></span></span>
-<span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">The Evidence:</span></span>'''</span>
+<span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:">The Evidence:</span></span>'''</span>
-<span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">None reported.</span></span></span>
+<span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family:">None reported.</span></span></span>
-<span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">Comments:</span></span>'''</span>
+<span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:">Comments:</span></span>'''</span>
-<span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">1. Reasons for cancellation given were slower than expected recruitment rate and difficulty engaging orthopaedic team owing to pre-existing belief that HBO was efficacious.</span></span></span>
+<span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family:">1. Reasons for cancellation given were slower than expected recruitment rate and difficulty engaging orthopaedic team owing to pre-existing belief that HBO was efficacious.</span></span></span>
-<span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">2. No report of any outcome from the 17 enrolled patients.</span></span></span>
+<span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family:">2. No report of any outcome from the 17 enrolled patients.</span></span></span>
-<span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">Appraised by:</span></span>'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">Craig Wilson c.c.wilson@live.co.uk; Friday, 24 November 2017</span></span></span>
+<span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:">Appraised by:</span></span>'''<span style="font-size:12.0pt"><span style="font-family:">Craig Wilson c.c.wilson@live.co.uk; Friday, 24 November 2017</span></span></span>
-<span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">Email:</span></span>'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">c.c.wilson@live.co.uk</span></span></span>
+<span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:">Email:</span></span>'''<span style="font-size:12.0pt"><span style="font-family:">c.c.wilson@live.co.uk</span></span></span>
-<span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">Kill or Update By:</span></span>'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">November 2022</span></span></span>
+<span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:">Kill or Update By:</span></span>'''<span style="font-size:12.0pt"><span style="font-family:">November 2022</span></span></span>
 [[File:Sumhorsa.gif|center|sumhorsa.gif]]

@@ Line 1: / Line 1: @@
-== <span style="font-size: 140%;">No data on the use of hyperbaric oxygen for open tibial fractures</span> ==
+<span style="line-height:normal">'''<span style="font-size:18.0pt"><span style="font-family:" times="" new="" roman",serif"="">No data on the use of hyperbaric oxygen for open tibial fractures</span></span>'''</span>
-== '''<span style="font-size: 12pt;">Clinical bottom line:</span>''' ==
+<span style="line-height:normal">'''<span style="font-size:14.0pt"><span style="font-family:" times="" new="" roman",serif"="">Clinical bottom line:</span></span>'''</span>
-{|
+{| class="Table" style="border:undefined"
 |-
-| <span style="font-size:medium;">'''1. Trial abandoned having recruited only 17 patients in total (target 36 in each group)'''</span>
 |}
-<span style="font-size:medium;">'''Citation/s:'''''''''&nbsp;''''''1.&nbsp;Williamson OD, Millar I, Venturoni C. Hyperbaric oxygen and the management of open tibial fractures. Journal of Bone and Joint Surgery – British Volume, Orthopaedic proceedings 2005; 88-B(Suppl II):323.</span>
+----
-<span style="font-size:medium;">'''Lead author's name and fax:''''''I. Millar&nbsp; I.Millar@alfred.org.au</span>
+<span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">Lead author's name and fax:</span></span>'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">I. Millar I.Millar@alfred.org.au</span></span></span>
-<span style="font-size:medium;">'''Three-part Clinical Question:''''''Does HBOT improve soft tissue healing in adult patients with open tibial fractures'''</span>
+<span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">Three-part Clinical Question:</span></span>'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">Does HBOT improve soft tissue healing in adult patients with open tibial fractures?</span></span></span>
-<span style="font-size:medium;">'''Search Terms:''' Open tibial fracture hyperbaric oxygen therapy</span>
+<span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">Search Terms:</span></span>'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">Open tibial fracture; crush injury</span></span></span>
-<span style="font-size:medium;">'''The Study:&nbsp;'''Non-blinded randomised controlled trial.</span>
+<span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">The Study:</span></span>'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">Non-blinded randomised controlled trial.</span></span></span>
-<span style="font-size:medium;">The Study Patients:'''Adults with lower leg fractures requiring extensive soft tssue and/or vascular repair (Gustillo class 3B and 3C fractures).'''</span>
+<span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">The Study Patients:</span></span>'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">Adults with lower leg fractures requiring extensive soft tssue and/or vascular repair (Gustillo class 3B and 3C fractures).</span></span></span>
-<span style="font-size:medium;">'''Control group''''''''':''' '''No HBOT, usual management.</span>
+<span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">Control group:''</span></span>'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">No HBOT, usual management.</span></span></span>
-<span style="font-size:medium;">'''Experimental group''''''''':''''''As above plus HBOT – dose not reported</span>
+<span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">Experimental group:</span></span>'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">As above plus HBOT – dose not reported.</span></span></span>
-<span style="font-size:medium;">'''The Evidence:'''</span>
+<span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">The Evidence:</span></span>'''</span>
-<span style="font-size:medium;">None reported.</span>
+<span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">None reported.</span></span></span>
-<span style="font-size:medium;">'''Comments:'''</span>
+<span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">Comments:</span></span>'''</span>
-<span style="font-size:medium;">1. Reasons for cancellation given were slower than expected recruitment rate and difficulty engaging orthopaedic team owing to pre-existing belief that HBO was efficacious.</span>
+<span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">1. Reasons for cancellation given were slower than expected recruitment rate and difficulty engaging orthopaedic team owing to pre-existing belief that HBO was efficacious.</span></span></span>
-<span style="font-size:medium;">2.No report of any outcome from the 17 enrolled patients.</span>
+<span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">2. No report of any outcome from the 17 enrolled patients.</span></span></span>
-<span style="font-size:medium;">'''Appraised by:''''''''''''Craig Wilson c.c.wilson@live.co.uk; Friday, 24 November 2017</span>
+<span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">Appraised by:</span></span>'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">Craig Wilson c.c.wilson@live.co.uk; Friday, 24 November 2017</span></span></span>
-<span style="font-size:medium;">'''Email:''' c.c.wilson@live.co.uk</span>
+<span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">Email:</span></span>'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">c.c.wilson@live.co.uk</span></span></span>
-<span style="font-size:medium;">'''Kill or Update By:''''''November 2022</span>
+<span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">Kill or Update By:</span></span>'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">November 2022</span></span></span>
 [[File:Sumhorsa.gif|center|sumhorsa.gif]]
-== <span style="display: block; text-align: center;"><span style="color: #7c00ff; font-size: 160%;">[[Acute_ischaemia|BACK]]</span></span> ==
+== <span style="display: block; text-align: center;"><span style="color: #7c00ff; font-size: 160%;">[[Crush_injuries|BACK]]</span></span> ==
 &nbsp;

@@ Line 1: / Line 1: @@
 ==<span style="font-size: 140%;">No data on the use of hyperbaric oxygen for open tibial fractures</span>==
-==<span style="font-size: 12pt;">Clinical bottom line:</span>==
+== <span style="font-size: 140%;">No data on the use of hyperbaric oxygen for open tibial fractures</span> ==
 {|
-| '''1. Trial abandoned having recruited only 17 patients in total (target 36 in each group)'''
+== '''<span style="font-size: 12pt;">Clinical bottom line:</span>''' ==
 |-
 |}
-**Lead author's name and fax:''' O.D.Williamson, I. Millar
+<span style="font-size:medium;">'''Citation/s:'''''''''&nbsp;''''''1.&nbsp;Williamson OD, Millar I, Venturoni C. Hyperbaric oxygen and the management of open tibial fractures. Journal of Bone and Joint Surgery – British Volume, Orthopaedic proceedings 2005; 88-B(Suppl II):323.</span>
-**Three-part Clinical Question:''' Does HBOT improve soft tissue healing in adult patients with open tibial fractures?
-**Search Terms:''' Open tibial fracture hyperbaric oxygen therapy
+<span style="font-size:medium;">None reported.</span>
-Non-blinded randomised controlled trial.
+<span style="font-size:medium;">'''Comments:'''</span>
-**The Study Patients:''' Adults with lower leg fractures requiring extensive soft tssue and/or vascular repair (Gustillo class 3B and 3C fractures).
+<span style="font-size:medium;">1. Reasons for cancellation given were slower than expected recruitment rate and difficulty engaging orthopaedic team owing to pre-existing belief that HBO was efficacious.</span>
-**Control group''': No HBOT, usual management.
+<span style="font-size:medium;">2.No report of any outcome from the 17 enrolled patients.</span>
-**Experimental group''': As above plus HBOT – dose not reported
+<span style="font-size:medium;">'''Appraised by:''''''''''''Craig Wilson c.c.wilson@live.co.uk; Friday, 24 November 2017</span>
-. Reasons for cancellation given were slower than expected recruitment rate and difficulty engaging orthopaedic team owing to pre-existing belief that HBO was efficacious.
+<span style="font-size:medium;">'''Email:''' c.c.wilson@live.co.uk</span>
-Email: c.c.wilson@live.co.uk
+<span style="font-size:medium;">'''Kill or Update By:''''''November 2022</span>
-**Kill or Update By:''' November 2020
+[[File:Sumhorsa.gif|center|sumhorsa.gif]]
-[[File:sumhorsa.gif|center|sumhorsa.gif]]
+== <span style="display: block; text-align: center;"><span style="color: #7c00ff; font-size: 160%;">[[Acute_ischaemia|BACK]]</span></span> ==
-==<span style="display: block; text-align: center;"><span style="color: #7c00ff; font-size: 160%;">[[Acute ischaemia  |  BACK]]</span></span>==
+&nbsp;